- Home
- LXEH vs CANF Comparison
LXEH vs CANF Comparison
Compare LXEH & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXEH | CANF |
|---|---|---|
| Founded | 2001 | 1994 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 5.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LXEH | CANF |
|---|---|---|
| Price | $0.27 | $4.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | ★ 2.0M | 74.6K |
| Earning Date | 03-15-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,585,942.00 | $560,000.00 |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.18 | $3.36 |
| 52 Week High | $50.08 | $46.60 |
Technical Indicators
Market Signals| Indicator | LXEH | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 64.56 |
| Support Level | $0.20 | $4.00 |
| Resistance Level | $0.39 | $4.32 |
| Average True Range (ATR) | 0.06 | 0.29 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 31.74 | 31.61 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.